Table 2. Subgroup analysis of overall survival and progression-free survival.

Subgroup	Description	Study	HR (95% CI)	P	P for heterogeneity	I2 (%)
OS
Year	Before 2017	9	0.898 (0.754–1.069)	0.227	0.61	0.00
	After 2017	9	0.496 (0.263–0.936)	0.03	<0.001	93.30
Country	Japan	11	0.905 (0.725–1.128)	0.374	0.062	43.20
	Other	7	0.464 (0.248–0.867)	0.016	<0.001	91.10
Sample size	Small	9	0.645 (0.445–0.934)	0.02	0.047	49.00
	Large	9	0.688 (0.399–1.185)	0.178	<0.001	94.20
MVI	MVI (+/−)	10	0.711 (0.406–1.244)	0.232	<0.001	93.50
	MVI only	6	0.566 (0.437–0.732)	<0.001	0.348	10.50
Study quality	Low	4	0.972 (0.630–1.499)	0.896	0.284	21.0
	High	14	0.616 (0.405–0.938)	0.024	<0.001	90.9
Regimen	mFOLFOX	1	0.140 (0.105–0.187)	<0.001	NA	NA
	Cisplatin + 5-FU	7	0.555 (0.403–0.764)	<0.001	0.148	36.70
	Other	10	0.940 (0.797–1.108)	0.461	0.304	15.10
BCLC	Stage C only	9	0.637 (0.509–0.797)	<0.001	0.307	15.2
	Stage B and C	6	0.660 (0.294–1.482)	0.314	<0.001	95.6
PFS
Year	Before 2017	6	0.752 (0.562–1.007)	0.056	0.162	36.80
	After 2017	7	0.453 (0.382–0.538)	<0.001	0.313	15.40
Country	Japan	7	0.626 (0.441–0.890)	0.009	0.009	64.70
	Others	6	0.482 (0.386–0.601)	<0.001	0.182	33.90
Sample size	Small	7	0.472 (0.363–0.613)	<0.001	0.461	0.00
	Large	6	0.620 (0.448–0.858)	0.004	<0.001	80.40
MVI	MVI (+/−)	6	0.602 (0.419–0.865)	0.006	<0.001	80.40
	MVI only	5	0.470 (0.350–0.631)	<0.001	0.276	21.70
Study quality	Low	3	0.509 (0.287–0.904)	0.021	0.173	43.1
	High	10	0.563 (0.437–0.725)	<0.001	0.001	68.7
Regimen	mFOLFOX	1	0.397 (0.319–0.495)	<0.001	NA	NA
	Cisplatin + 5-FU	6	0.478 (0.378–0.606)	<0.001	0.425	0.00
	Others	6	0.712 (0.533–0.952)	0.022	0.054	53.90
BCLC	Stage C only	7	0.507 (0.396–0.648)	<0.001	0.313	15.3
	Stage B and C	4	0.640 (0.387–1.058)	0.082	<0.001	87.8

OS, overall survival; PFS, progression-free survival; 5-FU, 5-flurouracil; MVI, macroscopic vascular invasion; HR, hazard ratio; NA, not available.